Patrick LEGEMBRE
  • E-mail :[email]
  • Phone : +33-668207640
  • Location : LIMOGES, France
Last update 2020-02-10 10:48:56.129

Patrick LEGEMBRE PhD Onco-Immunology

Course and current status

Patrick Legembre

45 years, Born in Evry (France), French. two kids

Present address:

  • Inserm U1262; Faculté de Médecine – 2 rue du Dr Marcland 87025 – Limoges Cedex.
  • Phone: (+33)-6-68207640;
  • E-mail: patrick.legembre@inserm.fr
  • Key works: breast cancer, lupus, inflammation, CD95, TNF receptors, Apoptosis, migration, calcium. 

EDUCATION

  • 2007- Habilitation to supervise research (HDR); University of Bordeaux; Immunology/Oncology.
  • 2002- Ph.D. degree; University of Bordeaux; Immunology/Oncology.

EMPLOYMENT

  • Nov 2019- now: Professor (Director of Research Inserm), U1262. Limoges/France.
  • Jan 2017- Oct 2019: Deputy Director U1242, Chemistry Oncogenesis Stress & Signaling (COSS), Ligue Contre Le cancer Team.
  • Jan 2015- Dec 2016- Director ER440. Ligue Contre Le cancer Team. Rennes/France.
  • Jan 2010-Dec 2014- Professor (Director of Research Inserm), U1085. Ligue Contre Le cancer team. Rennes/France.
  • Dec 2005-Dec 2009- Associate Professor (CR INSERM), UMR CNRS 5164 (Pr. Moreau JF). Bordeaux/France.
  • Sept 2002-Oct 2005- Postdoctoral fellow, (Pr Peter M). Ben May Institute For Cancer Research/ University of Chicago. Chicago/USA.

PATENTS

WO2010/063847; WO2014118317; WO2015189236; WO2015044229; WO2015158810; WO2015104284

Scientific Academy Society and committees membership

  • Member of National Ligue Contre Le Cancer Scientific Council (2013-2017)
  • Member of National INSERM scientific council-CSS2 (2008-2012)
  • Associate editor of the journal Recent Patents on Anti-Cancer Drug Discovery. (2009-2018)

Honors and Awards

  • 2018: Price “Jean Valade” Fondation de France.
  • 2016: Price “Ruban Rose Avenir”.
  • 2016: Price “Fondation Banque Populaire de l’Ouest Avenir”.
  • 2012-2017: Equipe “Ligue Contre Le Cancer”.
  • 2007-2012: ANR young scientist.

RESEARCH & PUBLICATIONS (5 recent publications over 60)/ h-index:23 (Scopus)

  1. Poissonnier A, Guégan JP, Nguyen HT, Best D, Levoin N, Kozlov G, Gehring K, Pineau R, Jouan F, Morere L,, Martin S, Thomas M, Lazaro E, Douchet I, Ducret T, van de Weghe P, Blanco P, Jean M, Vacher P and Legembre P. Nature Chemical Biology. 2018.             
  2. Poissonnier A, Sanséau D, Le Gallo M, Malleter M, Levoin N, Viel R, Morere L, Penna A, Blanco P, Dupuy A, Poizeau F, Fautrel A, Seneschal J, Jouan F, Ritz J, Forcade E, Rioux N, Contin C, Ducret T, Vacher A-M, Barrow PA, Flynn RJ, Vacher P, and Legembre P. Immunity. 2016.
  3. Malleter M, Tauzin S, Bessede A, Castellano R, Goubard A, Godey F, Leveque J, Jezequel P, Campion L, Campone M, Ducret T, Macgrogan G, Debure L, Collette Y, Vacher P, Legembre P. Cancer Res. 2013.
  4. Khadra N, Bresson-Bepoldin L, Penna A, Chaigne-Delalande B, Ségui B, Levade T, Vacher AM, Reiffers J, Ducret T, Moreau JF, Cahalan MD, Vacher P, Legembre P. PNAS. 2011. 
  5. Tauzin S, Chaigne-Delalande B, Selva E, Khadra N, Daburon S, Contin-Bordes C, Blanco P, Le Seyec J, Ducret T, Counillon L, Moreau JF, Hofman P, Vacher P and Legembre P. PLoS Biology. 2011.

CONFERENCE ORGANIZATION

Co-organizer of International Congress “Cancer Cell Death and Therapy 2017”, St. Malo (France), May 10-12, 2017.

Co-organizer of 1st International Congress “Cell Death in Cancer”, St. Malo (France), May 13-16, 2012.

 

Scientific summary

CD95 (also known as Fas) is considered as a death receptor and it belongs to the TNF (tumor necrosis factor) receptor family. Its ligand, CD95L is a transmembrane cytokine (m-CD95L), which can be cleaved by metalloproteases and released in the bloodstream as a soluble fragment (s-CD95L). While m-CD95L is found at the surface of immune cells where it orchestrates the elimination of transformed/infected cells and the immune contraction, s-CD95L behaves as a proto-oncogene enhancing the risk of metastatic occurrence in breast cancers. Our main goals are i) to decipher how CD95 switches from implementing cell death to non-apoptotic signaling pathways, ii) to identify the cells whose function is deregulated by the naturally processed ligand in breast cancers and iii) to develop original therapeutics that selectively inhibit the CD95-mediated non-apoptotic and pro-inflammatory signaling pathway.

Image d’exemple